ALLUVI: A THOROUGH DIVE INTO THE MEDICATION'S PROMISE

Alluvi, previously known as LY3414901, represents a noteworthy advancement in obesity management. This combined-action glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist demonstrates remarkable efficacy in early trial data, with substantial wei